Digital Cognitive Behavior Therapy Program for Suicide Prevention — TM2  

Depression Clinical Trial

Official title: Thrive-Montana: A Computerized Cognitive Behavior Therapy (cCBT) Program to Reduce Depression, Anxiety, Suicidal Ideation and Behaviors for Rural Montanans

Status Completed

Clinical Trial Summary

This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among adults. The first 450 participants will participate in a randomized waitlist controlled trial. The remaining 550 participants will be provided the program immediately upon enrolling

Clinical Trial Description

The efficacy of Thrive has been studied among patient and community populations and has shown to effectively reduce depression and anxiety symptoms among adults with moderate to severe depression symptoms at baseline.

This study will examine whether Thrive can also reduce suicidal thinking for persons exhibiting at least moderate depression symptoms. The first phase of the study will implement a randomized waitlist controlled trial. The second phase of the study will examine the effects in a open trial. Outcome assessments will occur at baseline, 4- and 8-weeks (12- and 16-weeks for the waitlist group) with a 6-month follow-up assessment for all participants. ;

Related Conditions & MeSH terms

• Anxiety
• Depression
• Suicidal Ideation

• NCT number: NCT03595254
• Study type: Interventional
• Source: Montana State University
• Status: Completed
• Phase: N/A
• Start date: November 16, 2018
• Completion date: April 8, 2020